What Management Said
Read the full Q3 2025 transcript ↗The third quarter of 2025 was marked by significant operational progress as we continue to scale the ZEVASKYN commercial launch to meet growing patient demand. We're seeing growing patient demand for ZEVASKYN, the first and only autologous cell-based gene therapy for the treatment of adult and pediatric patients with recessive dystrophic EB, or RDEB. We are happy to also report that demand for ZEVASKYN continues to grow.
In summary, we are very encouraged by the growing patient demand, patients actively progressing toward treatment, continued growth of the QTC site network, and a favorable market access landscape for ZEVASKYN. The current cash position, without accounting for anticipated revenue from ZEVASKYN, is expected to be sufficient to fund current and planned operations for over two years. This increase reflects the reclassification of R&D expenses as noted, along with increased headcount and professional costs associated with the commercial launch of ZEVASKYN.
Gao brings over 20 years of industry experience and is a recognized expert in gene therapy, especially in ophthalmology, which will be valuable as we advance our pipeline. Can you remind us then, in terms of revenue recognition from the time that you dose these patients, how long until revenue recognition? The revenue is recognized when the product is applied on the patient from an accounting standpoint.
What went well
- Commercial momentum kept building even without a first treatment yet: identified eligible patients at the QTCs more than doubled to roughly 30 (from a dozen-plus), and Abeona received signed ZEVASKYN Product Order Forms (ZPOFs, an informed-consent step) for 12 patients.
- A third QTC was activated - Children's Hospital Colorado, a highly recognized EB center - joining Lurie Chicago and Stanford, with several more centers advancing through onboarding.
- Market access broadened sharply: coverage policies were now published by all major commercial payers (UnitedHealthcare, Cigna, Aetna, Anthem and most Blue Cross Blue Shield plans), collectively covering more than 80% of commercially insured lives.
- On the government side, ZEVASKYN reached baseline coverage across all 51 state Medicaid programs and Puerto Rico effective October 1, 2025, and CMS established a permanent product J-code effective January 1, 2026 to simplify billing and reimbursement.
- The balance sheet remained strong at $207.5 million of cash and investments at September 30, 2025, providing more than two years of runway without any ZEVASKYN revenue.
- R&D fell to $4.2 million (from $8.9 million) and the net loss narrowed to $5.2 million (-$0.10 per share) from a $30.3 million loss (-$0.63) a year earlier; the pipeline advanced as ABO-503 (X-linked retinoschisis) was selected for the FDA's Rare Disease Endpoint Advancement pilot.
What went wrong
- The headline negative: the first commercial patient treatment slipped from Q3 to Q4 2025 after a manufacturing quality issue.
- A full drug-product batch had to be rejected because a new rapid sterility assay - an FDA requirement added during BLA review, not used in the clinical trials - returned a false positive; gold-standard USP retesting confirmed sterility but results came after the lot's expiration, so it could not be released.
- As a precaution, Abeona temporarily paused collecting further patient biopsies while it investigated and optimized the assay, only resuming biopsy collection in November 2025.
- SG&A rose again to $19.3 million (from $6.4 million) on the reclassification of R&D and continued commercial-launch spending.
- The 25-day manufacturing process plus a planned FDA-mandated year-end plant shutdown (mid-December to early January) added to near-term timing uncertainty, and the identification-to-treatment cycle remained about three months.
Guidance Changes
| Metric | Period | Current guidance |
|---|---|---|
| First commercial treatment | Q4 2025 | Shifted to Q4 2025 following release-assay optimization; biopsies resumed November 2025 |
| Company-wide profitability | 1H 2026 | Still first half of 2026; management sees no significant impact from the first-treatment delay |
| ZPOFs / demand | Current | 12 signed ZEVASKYN Product Order Forms; identified QTC patients more than doubled to ~30 |
| Market access | Current | >80% of commercial lives covered by published policies; all 51 Medicaid programs plus Puerto Rico effective Oct 1, 2025; CMS J-code effective Jan 1, 2026 |
| Year-end plant shutdown | Dec 2025-Jan 2026 | FDA-mandated maintenance/recalibration shutdown from mid-December for about a month |
Performance Breakdown
| Metric | YoY | Note |
|---|---|---|
| R&D expense | $4.2M vs $8.9M | Costs capitalized into inventory and select production/engineering-run costs reclassified to SG&A after approval. |
| SG&A expense | $19.3M vs $6.4M | Reclassification of R&D plus increased headcount and professional costs for the commercial launch. |
| Net loss | -$5.2M vs -$30.3M | Lower operating loss year over year; no PRV gain in the quarter (that was recognized in Q2). |
| EPS | -$0.10 vs -$0.63 | Narrower net loss. |
| Cash and investments | $207.5M (Sept 30, 2025) | More than two years of runway without ZEVASKYN revenue. |
| Identified QTC patients | ~30 (from ~12) | Growing demand at the QTCs, excluding the larger non-QTC referral pool; 12 ZPOFs signed. |
Earnings Call Themes & Trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Manufacturing / sterility assay | On track | A false-positive on a newly required rapid sterility assay forced a lot rejection and a temporary biopsy pause; assay optimized, validated and submitted, biopsies resumed November 2025, pushing first treatment to Q4. | — |
| Commercial demand | ~50 identified | QTC-identified patients doubled to ~30; 12 ZPOFs signed; management expects high conversion given motivated, severe patients. | — |
| Market access | Early wins | All major commercial payers have published policies (>80% of commercial lives); Medicaid baseline coverage across all states effective Oct 1; permanent CMS J-code effective Jan 1, 2026. | — |
| QTC network | 2 centers | Third center (Children's Hospital Colorado) activated; several more in onboarding. | — |
| Pipeline / team | - | ABO-503 (XLRS) selected for FDA RDEA pilot program; Dr. James A. Gao appointed SVP, Head of Clinical Development and Medical Affairs. | — |
Q&A Summary
Jefferies asked the timeline for the 12 ZPOF patients to be treated.
Management said the patients are at various points in the journey; some biopsies were scheduled for November and early 2026, and metrics will normalize as patients move through - clearer by Q1 2026.
Analysts asked whether the delay pushes out the profitability timeline.
Management said no significant impact - it continues to expect a profitable business in the first half of 2026.
Cantor asked whether any biopsies collected before the pause would need to be repeated.
Abeona had paused collecting further biopsies out of caution when the issue arose, so no patients were left in limbo needing re-biopsy at that time.
H.C. Wainwright asked about expected attrition among the 12 ZPOF patients.
Management expects high conversion because these are motivated, severe patients whom QTCs prioritize; success rates in trials were high and the release-assay issue is resolved.
Alliance Global Partners asked how many of the ~30 patients are on background Vyjuvek/Filsuvez.
Abeona lacks direct visibility but expects the vast majority have used Vyjuvek and/or Filsuvez, reflecting the unmet need for multiple treatment options; prior gene-therapy records can even ease payer access.
More on Abeona Therapeutics Inc.
Reported 2025-11-12 · figures from the Abeona Therapeutics Inc. Q3 2025 earnings call.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.